Tribulations and (clinical) trials in cystic fibrosis

J Cyst Fibros. 2021 Mar;20(2):188-190. doi: 10.1016/j.jcf.2020.12.017. Epub 2021 Jan 3.

Authors

R Elaine Cagnina¹, Gregory S Sawicki²

Affiliations

¹ Division of Pulmonary Medicine, Boston Children's Hospital, United States; Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA, United States. Electronic address: rcagnina@bwh.harvard.edu.
² Division of Pulmonary Medicine, Boston Children's Hospital, United States. Electronic address: Gregory.Sawicki@childrens.harvard.edu.

PMID: 33408059
DOI: 10.1016/j.jcf.2020.12.017

No abstract available

Publication types

Editorial
Introductory Journal Article

MeSH terms

Aminophenols / therapeutic use
Aminopyridines / therapeutic use
Benzodioxoles / therapeutic use
Cannabinoid Receptor Agonists / therapeutic use*
Chloride Channel Agonists / therapeutic use*
Clinical Trials as Topic
Cystic Fibrosis / drug therapy*
Dronabinol / analogs & derivatives
Dronabinol / therapeutic use
Drug Combinations
Humans
Indoles / therapeutic use
Quinolones / therapeutic use

Substances

Aminophenols
Aminopyridines
Benzodioxoles
Cannabinoid Receptor Agonists
Chloride Channel Agonists
Drug Combinations
Indoles
Quinolones
lumacaftor, ivacaftor drug combination
tezacaftor, ivacaftor drug combination
Dronabinol
lenabasum